Glaxo | The FCPA Blog

Editors

Harry Cassin
Publisher and Editor

Andy Spalding
Senior Editor

Jessica Tillipman
Senior Editor

Bill Steinman
Senior Editor

Richard L. Cassin
Editor at Large

Elizabeth K. Spahn
Editor Emeritus

Cody Worthington
Contributing Editor

Julie DiMauro
Contributing Editor

Thomas Fox
Contributing Editor

Marc Alain Bohn
Contributing Editor

Bill Waite
Contributing Editor

Shruti J. Shah
Contributing Editor

Russell A. Stamets
Contributing Editor

Richard Bistrong
Contributing Editor

Eric Carlson
Contributing Editor

Posts Tagged: Glaxo

U.S., China enforcement crossfire creates new risks

Lisa Prager and Lara Covington October 18, 2013

At the beginning of this year, China’s president Xi Jinping promised to fight both “tigers” and “flies” — high-ranking and low-ranking corrupt officials — in his crackdown on corruption. Since then, the anti-graft campaign has led to the conviction of Bo Xilai and to the front-page investigations of foreign companies in the pharmaceutical and oil and gas sectors, among others.… Continue Reading

Bribery part of GSK business plan, China police say

Richard L. Cassin September 4, 2013

Image courtesy of GlaxoSmithKlineA police investigation in China has found that drugmaker GlaxoSmithKline’s alleged bribery of doctors ‘was coordinated by the British company and was not the work of individual employees,’ according to a report Tuesday by Reuters.… Continue Reading

Drug sellers ‘take vacations’ amid China anti-graft campaign

Hui Zhi August 26, 2013

Pharmas have told their sales teams to halt all activity in China to avoid being caught in the nationwide “enforcement storm,” according to the Guangdong-based Yangcheng Evening News.

“It is rumored that police in plain clothes are patrolling in hospitals; drug sales representatives will be fined 500 yuan ($81) and regional sales managers 1000 yuan ($162) once being caught in hospitals,” an unidentified sales representative told the paper.… Continue Reading

GSK In China: A Game Changer in Compliance

Thomas Fox August 21, 2013

The entry of the Chinese government into the international fight against corruption and bribery is truly a game-changer. While there may be many reasons for this very public move by the Chinese government, it is clear that foreign companies are now on notice.… Continue Reading

Sanofi hit with China bribe probe

Richard L. Cassin August 11, 2013

China state media reported Saturday that French drugmaker Sanofi SA is under investigation for allegedly bribing doctors to increase sales.

The Xinhua news agency said more than 500 Chinese doctors are suspected of accepting bribes from the company.… Continue Reading

Can we relax yet?

Richard L. Cassin August 8, 2013

Professor Peter J. Henning of Wayne State University Law School (Photo courtesy of Wayne Law)“Over the last decade, since the passage of the Sarbanes-Oxley Act in 2002, publicly traded corporations have poured significant resources into their compliance programs to prevent wrongdoing, or to at least be an early warning system for what might become a problem.… Continue Reading

Problem du jour: Dealing with travel agents

Rob Morris and Juvenia Ho August 8, 2013

The risks of working with travel agents are coming to light amid recent allegations that at least one agent in China and maybe many more used slush funds to make illicit payments on behalf of a pharmaceutical client.… Continue Reading

Quick look at Big Pharma’s U.S. rap sheet

Richard L. Cassin August 7, 2013

Recent turbulence in China for drug makers follows big problems for members of the industry in the United States, where they’ve paid billions in criminal fines and civil penalties.

Here’s a quick rundown of their U.S.… Continue Reading

Baxter confirms China payment offenses

Richard L. Cassin August 5, 2013

Drug and medical device maker Baxter International Inc. told the Wall Street Journal last week that following whistleblower complaints, it investigated allegations and found improper expense payments by a China joint venture.… Continue Reading

Spread of GSK contagion to other countries, industries now ‘highly likely’

Scott Graham August 1, 2013

The GSK China bribery investigators are probably going to name several other significant foreign companies in the coming days and weeks. The State Administration for Industry & Commerce (SAIC) has already announced that investigations into several other pharmaceutical companies have begun.… Continue Reading

With flashy pharma sweep, China steps into global enforcement role

Richard L. Cassin July 30, 2013

Here’s a thoughtful comment from a U.S.-based compliance professional who asked not to be named:

* * *

I think that as China continues to march to the largest economy in the world it is going to have increasing influence in the world in many areas.… Continue Reading

More arrests, confessions reported in China pharma scandal

Richard L. Cassin July 27, 2013

China state media reported Friday that police have detained 18 more people in the growing bribery investigation of U.K. drug maker GlaxoSmithKline.

Those detained include company employees and medical personnel, according to a report by the Guardian.… Continue Reading